aTyr Pharma, Inc. (LIFE) Stock Rating Lowered by Zacks Investment Research

aTyr Pharma, Inc. (NASDAQ:LIFE) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research note issued to investors on Thursday.

According to Zacks, “aTyr Pharma, Inc. is a bio-therapeutics company. The Company is involved in the discovery and development of medicines for severe, rare diseases of physiological modulators. aTyr Pharma, Inc. is a based in SAN DIEGO, United States. “

Several other equities research analysts also recently commented on the stock. BMO Capital Markets restated a “hold” rating on shares of aTyr Pharma in a research report on Wednesday, May 24th. Piper Jaffray Companies started coverage on shares of aTyr Pharma in a research report on Thursday, September 7th. They issued an “overweight” rating and a $7.00 price target for the company. Finally, ValuEngine downgraded shares of aTyr Pharma from a “sell” rating to a “strong sell” rating in a research report on Wednesday, September 6th. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and one has issued a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and an average target price of $4.27.

aTyr Pharma (NASDAQ:LIFE) opened at 3.70 on Thursday. The firm’s market capitalization is $88.20 million. The company’s 50 day moving average price is $3.26 and its 200 day moving average price is $3.45. aTyr Pharma has a 12 month low of $2.10 and a 12 month high of $4.45.

aTyr Pharma (NASDAQ:LIFE) last issued its earnings results on Monday, August 14th. The biotechnology company reported ($0.51) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.57) by $0.06. Analysts anticipate that aTyr Pharma will post ($2.18) EPS for the current year.

TRADEMARK VIOLATION WARNING: This article was first posted by Chaffey Breeze and is owned by of Chaffey Breeze. If you are viewing this article on another domain, it was illegally copied and reposted in violation of US and international copyright & trademark legislation. The original version of this article can be viewed at https://www.chaffeybreeze.com/2017/09/16/atyr-pharma-inc-life-stock-rating-lowered-by-zacks-investment-research-2.html.

In other news, CEO John Mendlein purchased 37,736 shares of aTyr Pharma stock in a transaction that occurred on Thursday, August 31st. The stock was acquired at an average price of $2.65 per share, for a total transaction of $100,000.40. The purchase was disclosed in a filing with the SEC, which is accessible through this link. Also, Director Paul Schimmel purchased 94,336 shares of aTyr Pharma stock in a transaction that occurred on Thursday, August 31st. The stock was purchased at an average price of $2.65 per share, with a total value of $249,990.40. Following the transaction, the director now owns 40,440 shares in the company, valued at approximately $107,166. The disclosure for this purchase can be found here. 33.30% of the stock is currently owned by corporate insiders.

A hedge fund recently raised its stake in aTyr Pharma stock. Renaissance Technologies LLC lifted its position in aTyr Pharma, Inc. (NASDAQ:LIFE) by 1.8% in the 1st quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 38,800 shares of the biotechnology company’s stock after acquiring an additional 700 shares during the quarter. Renaissance Technologies LLC owned approximately 0.16% of aTyr Pharma worth $136,000 as of its most recent filing with the SEC. Hedge funds and other institutional investors own 46.66% of the company’s stock.

About aTyr Pharma

aTyr Pharma, Inc is a clinical-stage biotherapeutics company. The Company is engaged in the discovery and clinical development of medicines for patients suffering from severe, rare diseases using its Physiocrine biology, a discovered set of physiological modulators. The Company focuses on the development of Physiocrine-based therapeutics for the treatment of rare diseases, including facioscapulohumeral muscular dystrophy (FSHD) and limb-girdle muscular dystrophy (LGMD) 2B.

Receive News & Ratings for aTyr Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for aTyr Pharma Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply